The accuracy reached 88% according to the cetuximab response.255 The combination of cetuximab with either gefitinib (Iressa, and ZD1839, EGFR inhibitor) or erlotinib (Tarceva, and OSI-774, EGFR inhibitor) was investigated in HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.